Physician profile
Michael Salter
NPI 1841553864
$3,459.04
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,135 · 2020: $836 · 2021: $971 · 2022: $135 · 2023: $362 · 2024: $20.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $514.21 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $342.80 | 2019-2023 | |
| Glaxosmithkline, LLC. | $273.17 | 2019-2023 | Shingrix |
| Astrazeneca Pharmaceuticals Lp | $235.81 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $160.81 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.73 | 2019-2023 | Synjardy, Tradjenta, Jardiance |
| Philips North America LLC | $151.33 | 2019-2021 | |
| Lilly USA, LLC | $151.11 | 2019-2023 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $132.63 | 2019-2022 | |
| Abbott Laboratories | $128.62 | 2021-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $125.44 | 2020-2023 | Xarelto |
| Amarin Pharma, INC. | $119.94 | 2019-2020 | |
| Abbvie INC. | $113.19 | 2021 | |
| Eisai INC. | $103.55 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.04 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $88.21 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $87.22 | 2020-2022 | |
| Allergan, INC. | $81.57 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.26 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $68.11 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $55.56 | 2021-2022 | |
| Genentech USA, INC. | $44.46 | 2019-2021 | |
| Amgen INC. | $27.50 | 2019 | |
| Medtronic, INC. | $24.05 | 2023 | Intellis Adaptivestim |
| Exact Sciences Corporation | $21.21 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $18.12 | 2023 | Gemtesa |
| Zyla Life Sciences, INC. | $18.06 | 2019 | |
| Shire North American Group INC | $15.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.14 | 2021 | |
| Horizon Therapeutics Plc | $11.70 | 2019 | |
| Merck Sharp & Dohme LLC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Salter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.